E2F transcription factors and digestive system malignancies: how much do we know?
about
E2F8 is a Potential Therapeutic Target for Hepatocellular CarcinomaThe genotype of the transporter associated with antigen processing gene affects susceptibility to colorectal cancer in Japanese.Genome-wide analysis of the oxyntic proliferative isthmus zone reveals ASPM as a possible gastric stem/progenitor cell marker over-expressed in cancer.microRNA-17 Is the Most Up-Regulated Member of the miR-17-92 Cluster during Early Colon Cancer EvolutionThe TRAF-interacting protein (TRAIP) is a novel E2F target with peak expression in mitosisAnalysis of salivary microRNA expression profiles and identification of novel biomarkers in esophageal cancer.Analysis of cis-Regulatory Elements in Gene Co-expression Networks in Cancer.The Spectrum of E2F in Liver Disease--Mediated Regulation in Biology and Cancer.miR-31 promotes proliferation of colon cancer cells by targeting E2F2.A functional variant at the miRNA binding site in E2F1 gene is associated with risk and tumor HPV16 status of oropharynx squamous cell carcinoma.E2F transcription factors and digestive system malignancies: how much do we know?Reduced mRNA expression levels of MBD2 and MBD3 in gastric carcinogenesis.Transcription factor E2F3a regulates CASP8AP2 transcription and enhances sensitivity to chemotherapeutic drugs in acute lymphoblastic leukemia.High expression of karyopherin-α2 and stathmin 1 is associated with proliferation potency and transformation in the bile duct and gall bladder epithelia in the cases of pancreaticobiliary maljunction.miR-155 regulates the proliferation and cell cycle of colorectal carcinoma cells by targeting E2F2.Differential role of Wnt signaling and base excision repair pathways in gastric adenocarcinoma aggressiveness.A computational framework for complex disease stratification from multiple large-scale datasets.
P2860
Q33776715-B8848D0A-EEE8-497B-A036-993FE8143AFDQ33857469-9AFFA3CC-4C6D-4305-B4BF-E66D643AE475Q35692884-434BCB66-EC6C-411C-9472-872172D58880Q35806198-A2AC0E16-F16C-4090-B835-47B87AA3E5FAQ36356204-B749CE04-5390-411E-8568-BA9DEC7559D7Q38430222-E68AD1E2-C215-470C-94AD-6B72A128A1DAQ38604264-EA6FA770-85DA-428C-8703-7CA2D51F39CFQ38633009-9AE0E813-8516-4460-842C-3EF6409E73FCQ38943434-10DA66EA-6F37-4ACE-B6D6-2E240D1DDAA5Q40495776-97BD29FE-ABD2-449E-A2AB-42132F88E921Q42772377-C57E6099-DBA9-44CC-9A31-E005F22AC852Q44401460-D1C32666-6086-4F3F-93B0-B239142CE54BQ51416390-C318BD79-8111-4ED2-84BD-6E32812B6E23Q51685400-30DDBAFF-6A34-48EE-A4FC-E904E62C8786Q53053623-328A4F08-5028-4D0E-AF53-30BF5B8DC77BQ53652240-A46EC016-AA7A-4BEE-B007-F68C8D9BAE91Q55139050-FB29FB28-78AE-4BD0-9FC1-10EC28CB3F15
P2860
E2F transcription factors and digestive system malignancies: how much do we know?
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
E2F transcription factors and digestive system malignancies: how much do we know?
@en
type
label
E2F transcription factors and digestive system malignancies: how much do we know?
@en
prefLabel
E2F transcription factors and digestive system malignancies: how much do we know?
@en
P2860
P356
P1476
E2F transcription factors and digestive system malignancies: how much do we know?
@en
P2093
Athanasios Xanthoulis
Dina G Tiniakos
P2860
P304
P356
10.3748/WJG.V19.I21.3189
P407
P577
2013-06-01T00:00:00Z